Adding PD1 Inhibitor to Neoadjuvant Chemotherapy Significantly Increases the pCR Rate in High-Risk, Early-Stage ER-positive, HER2-negative Breast Cancer By Ogkologos - February 12, 2025 1076 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 7FL and KEYNOTE-756 studies Source RELATED ARTICLESMORE FROM AUTHOR Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy ESMO Welcomes European Parliament Calls to Strengthen and Protect Europe’s Cancer Workforce No improvement in OS, but more grade 3 or higher AEs with atezolizumab plus SBRT among patients with inoperable early-stage NSCLC MOST POPULAR Into the archives: the story of HPV and cervical cancer November 21, 2022 Air Force Academy Cadet Donates 19-Inch Afro and Fundraises $39,000 for... July 7, 2021 Two-Time Breast Cancer Warrior Left Devastated After Package Full of Meds... June 25, 2020 Bride’s Escorted Down Aisle By Dad Of Organ Donor Who Saved... October 11, 2021 Load more HOT NEWS Teen Created App To Help His Non-Verbal Sister And Others Like... Alabama’s Ventilator Rationing Plan Discriminates Against Disabled & Ill Patients, Advocacy... Having a Heart Attack May Make Breast Cancer Grow Faster Studying “Total Diet” and Its Impact on Health, Including Cancer Risk
